ANTIHYPERTENSIVE EFFECT OF TRIMEPRANOL, A NEW BETA-BLOCKING AGENT

  • 1 January 1978
    • journal article
    • research article
    • Vol. 16  (4) , 183-188
Abstract
Trimepranol (TMP) is a new propranolol-like, non-selective .beta.-adrenoreceptor blocking drug. Its antihypertensive effect vs. placebo was evaluated in a double-blind cross-over study in 25 ambulatory patients, whose supine diastolic blood pressure (BP) was at least 95 mm Hg. After 4 wk treatment with placebo, the dose of TMP was titrated weekly until the supine diastolic BP was below 95 mm Hg or intolerable side effects occurred. The trimepranol dose determined was 10 mg b.i.d. (twice daily) for 3 patients, 20 mg b.i.d. for 2 patients and 40 mg b.i.d. for 10 patients. The subsequent double-blind cross-over study consisted of two 6-wk treatment periods, either with trimepranol followed by placebo (Group I) or in reverse order (Group II). BP and heart rate at the end of these periods were compared. Supine BP fell from 156 .+-. 3/105 .+-. 2 mm Hg at the end of placebo periods to 140 .+-. 2/93 .+-. 1 mm Hg (P < 0.001) for systolic and diastolic BP at the end of trimepranol periods, when the data of Groups I and II are pooled. In 19 of 25 patients, supine diastolic BP declined below 95 mm Hg during the trimepranol period. A statistically significant correlation was found between the antihypertensive and bradycardic effects of trimepranol. Mild side effects occurred in 8 patients during trimepranol period and in 9 patients during placebo period. No significant changes occurred in the heart volumes of the patients. Trimepranol b.i.d. is an effective antihypertensive agent.

This publication has 1 reference indexed in Scilit: